A startup in San Francisco called Elevian has rounded up $5.5 million in seed cash to pursue its work on a regenerative medicine program.
The big idea here is that research at Stanford and Harvard found that “young blood” has a regenerative impact on organs. And they believe as a consequence that boosting GDF11 — growth differentiation factor 11 — could play an anti-aging role in humans.
The founders have licensed the tech they’re working on from Harvard.
Bold Capital, WTI, Stanford StartX fund, Longevity fund, Kizoo Ventures, Thynk Capital, and other investors chipped in.
Cue the big dreams.
“Elevian is helping to lead a revolution in longevity. We are proud to support them as investment partners,” said Peter Diamandis, founding investor.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,700+ biopharma pros who read Endpoints News by email every day.Free Subscription